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Abstract
A workshop sponsored by the NIDDK and the NCI on “Pancreatitis-Diabetes-Pancreatic Cancer”
focused on the risk factors of chronic pancreatitis (CP) and diabetes mellitus (DM) on the
development of pancreatic ductal adenocarcinoma (PDAC). Sessions were held on a) an overview
of the problem of PDAC, b) CP as a risk factor for PDAC, c) DM as a risk factor for PDAC, d)
pancreatogenic, or type 3c DM (T3cDM), e) genomic associations of CP, DM, and PDAC, f)
surveillance of high-risk populations and early detection of PDAC, and g) effects of DM treatment
on PDAC. Recent data and current understandings of the mechanisms of CP- and DM-associated
factors on PDAC development were discussed, and a detailed review of the possible risks of DM
treatment on the development of PDAC was provided by representatives from academia, industry,
and the Food and Drug Administration. The current status of possible biomarkers of PDAC and
surveillance strategies for high-risk populations were discussed, and the gaps in knowledge and
opportunities for further research were elucidated. A broad spectrum of expertise of the speakers
and discussants provided an unusually productive workshop, the highlights of which are
summarized in the accompanying article.
INTRODUCTION
To better understand the mechanisms and potential interconnections between pancreatitis,
diabetes and pancreatic ductal adenocarcinoma (PDAC), the National Institute of Diabetes,
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Digestive & Kidney Disease (NIDDK) and the National Cancer Institute (NCI) cosponsored
a workshop in Bethesda, Maryland, USA on June 12–13, 2013. The workshop was designed
to bring together experts from academic institutions, industry and government agencies to
present relevant data and perspectives on questions related to the risk and development of
pancreatic cancer.
Twenty-seven presenters and seven discussants were joined by twenty-one poster
presentations (a complete agenda and list of presenters is available as supplementary
material at www.pancreasjournal/sdc). The workshop was dedicated to the memory of
George S. Eisenbarth, MD, PhD, a visionary mentor and investigator in the field of diabetes
who succumbed to pancreatic cancer in November 2012. The program included six sessions:
(1) Statement of the Problem of PDAC, (2) Pancreatitis as a Rsk Factor for PDAC, (3)
Diabetes as a Risk Factor for PDAC, (4) Pancreatogenic (Type 3c) Diabetes, (5)
Surveillance of High-risk Populations and Early Detection of PDAC, and (6) Effects of DM
Treatment on PDAC. In addition, the workshop included state of the art lectures on
Overview of PDAC and on Genomic Associations of Chronic Pancreatitis, Diabetes
Mellitus, and PDAC. The highpoints of each session are summarized below.
OVERVIEW OF THE PROBLEM
In contrast to dramatic declines in cancer-related deaths from other malignancies (i.e., lung
and bronchus, breast, colorectal, and prostate cancer), progress in the management of PDAC
has been slow and the incidence of deaths due to PDAC continues to rise [1]. The known
risk factors for PDAC include tobacco exposure, longstanding diabetes, obesity, advanced
age, exposure to benzenes, family history, and chronic pancreatitis (Table 1) [2]. It is
generally believed that unless the cancer risk in a given population increases 8–10 fold over
average risk, there is no cost-benefit advantage to screening. In selected syndromes such as
familial pancreatic cancer, Peutz-Jeghers syndrome, familial atypical mole and melanoma
syndrome, familial pancreatitis or in selected families with BRCA mutations, the risk does
approach or exceed this threshold. In these circumstances, screening with either endoscopic
ultrasound (EUS) or magnetic resonance imaging is justified [3].
On the molecular level, the driving oncogene for this malignancy appears to be KRAS [4].
In addition to activating mutations of this gene, other pathways are frequently suppressed,
such as p16, p53, and DPC4. However, a family history is still more important than mutation
screening for predicting the risk of PDAC. Precursor lesions for invasive disease include
pancreatic intraepithelial neoplasms (PanINs) or benign tumors with malignant potential,
such as intraductal-papillary mucinous neoplasms (IPMNs) or mucinous cystic neoplasms.
Histologically, the invasive malignant lesion is dominated by an intense desmoplastic
stroma, and the role of the stromal compartment is incompletely understood but thought to
play a major role in the aggressive behavior of this malignancy. It has been suggested that
the desmoplastic stroma may be a barrier to effective drug delivery. Although new
chemotherapy regimens, such as FOLFIRINOX or gemcitabine plus nab-paclitaxel, have
been introduced, these regimens are not free of toxicity and add little to long-term survival.
For these reasons, a better understanding of the unique characteristics of PDAC is needed in
order to improve early detection, treatment, and prevention.
CHRONIC PANCREATITIS (CP) AS A RISK FACTOR FOR PDAC
Understanding the common pathways for CP and PDAC may help to identify high risk
patients and facilitate the development of effective screening tools. Epidemiologically,
pancreatitis can be considered as a disease continuum: starting with an attack of acute
pancreatitis (AP), leading to recurrent AP in some patients (about 20–30%), then
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progression to CP in some (about 10%) and ultimately development of PDAC in a subset of
CP patients [5]. Risk of progression from AP to CP seems to be higher in patients with a
history of continuous tobacco smoking or alcohol drinking [5]. The precise risk factors and
mechanisms involved with this progression have yet to be determined however.
One of the challenges in epidemiology studies of pancreatitis and/or diabetes with PDAC is
reverse causality [6]. While long-standing CP clearly increases risk for PDAC, PDAC also
causes AP and CP. Likewise, while long-standing diabetes increases risk for PDAC, PDAC
itself causes glucose intolerance and diabetes as a paraneoplastic process. Thus, great care
must be given in evaluating the timing, context and comparison groups in epidemiology and
database studies of PDAC risk association and causality.
Environmental and genetic factors contribute to the risk for AP, CP and PDAC, with
hereditary CP (HCP) clearly having the largest genetic contribution [6]. Familial studies and
candidate gene testing have established PRSS1, SPINK1, CTRC, CFTR, CASR and GGT1 as
susceptibility loci for CP (PMID 20059346, 23462328). Recently, a large two-stage GWAS
analysis identified and replicated PRSS1-PR SS2 and X-linked CLDN2 as susceptibility loci
for CP [7]. The highest cancer risks have been observed in patients with hereditary
pancreatitis—a rare genetic form of pancreatitis with mutations of the cationic trypsinogen
gene (PRSS1) with an onset at an early age. In subjects with hereditary pancreatitis, the risk
of PDAC is about 50 times greater than in the corresponding background population, and the
lifetime risk of developing PDAC is about 70 percent [8], although the life-time risk in non-
smokers with HP may be less than 20% [9].
The inflammatory milieu is important in both CP and PDAC, and there is evidence that this
component may promote the epithelial-to-mesenchymal transition of pancreatic cells [10],
which is a component of oncogenesis. In KRASG12D-engineered mice, PanIN lesions have
been associated with acinar-to-ductal metaplasia (ADM) [11, 12], a condition where the
phenotypic characteristics of the acinar cells are changed and cells express ductal markers
such as CK19 and Sox9 [13, 14]. Inducing even one episode of acute pancreatitis in mice
with KRASG12d mutation may lead to feed-forward activation loops with persistent NF-κb
activation (a pro-inflammatory, anti-apoptotic mediator), with a marked increase in PDAC
development [15, 16]. These recent findings provide a possible mechanistic pathway
between chronic inflammation and PDAC.
The Role of Stellate Cell Activation in PDAC
Pancreatic stellate cells (PSCs) constitute roughly 4% of all pancreatic cells and are thought
of as specialized myofibroblasts that are regulated by autocrine and paracrine stimuli [17,
18]. PSCs promote tumor progression, metastasis and resistance to chemotherapy, and thus
play a central role in PDAC (as well as CP). These specialized cells are now known to be
activated by ethanol and its metabolites and by several factors that are upregulated during
pancreatic injury including growth factors, cytokines and oxidant stress. Conditioned media
from cultured PSCs can also alter apoptosis – the result being protection of pancreatic
cancer cells from chemo-and radiation-induced apoptosis. Furthermore, the dense network
of collagen and other matrix proteins may prevent circulating chemotherapeutic agents from
reaching PDAC cells. Strategies are being developed to cirmumvent the protective barrier
for PDAC cells that are generated by PSCs and improve delivery of therapeutic agents to the
target.
Role of CCK in PDAC Development
The gastrointestinal peptide cholecystokinin (CCK) and the related peptide gastrin act on
CCK receptors to regulate pancreatic digestive enzyme release, gastric acid stimulation, and
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GI tract growth. CCK is released in response to dietary fat; epidemiologic studies show an
increased incidence of CP in countries were fat consumption is high, and CCK blood levels
have been reported to be elevated in patients with CP. CCK-B receptors are the primary
receptor type detected in the normal human pancreas and are markedly over-expressed in
pancreatic cancer [19]. CCK receptors have been identified on PSCs, and stimulation of
these receptors produces collagen and fibrosis, features common to both CP and PDAC [20–
22]. In animal models, CCK receptors have been recently described on very early PanINs in
mice [23] and receptor blockade halts PanIN progression and reverses fibrosis. A splice
variant in the CCK-B receptor known as CCK-C has been identified in human PDAC which
results from a germline single nucleotide polymorphism (SNP) [24].
DIABETES AS A RISK FACTOR FOR PDAC
Obesity, diabetes mellitus, and glucose intolerance all have been associated with increased
pancreatic cancer risk (Table 1). A study of 29,133 Finnish male smokers revealed that the
presence of diabetes mellitus and, independently, elevated insulin concentrations both
showed a significant 2-fold increased risk of the subsequent development of PDAC more
than 10 years after baseline [25]. These results support the hypothesis that exposure to
higher insulin concentrations and insulin resistance affects the risk of exocrine pancreatic
cancer.
These epidemiologic findings support the laboratory observations that PDAC is
characterized by a constituitive over-expression of insulin receptors and insulin-like growth
factor receptors [26]. The trophic effects of these enhanced signaling systems are also the
target for the interaction of metformin in PDAC [27], which has attracted much recent
interest.
Combined chronic pancreatitis and diabetes risk on pancreatic cancer
A recent study from Taiwan indicated that the hazard ratio (HR) for subsequent PDAC in
individuals with the combined factors of CP and diabetes was increased 33-fold over
controls [28], but the forms of diabetes and CP were not further characterized. The ideal
model to study this complex relationship is hereditary pancreatitis (HP), a rare autosomal
dominant inheritance disease caused by a mutation of the PRSS1 gene. Pancreatic
insufficiencies occur early, and the median age at onset of exocrine insufficiency and
diabetes is 29 and 38 years, respectively. Almost all patients experience these complications
during their life span. In HP patients, the cumulative risk of PDAC at 50, 60, and 75 years
are 10 percent, 19 percent, and 54 percent, respectively [29]. HP is associated with a high
relative and absolute risk of PDAC as compared to the general population (SIR: 87). While
only 26% of patients in this French study developed diabetes mellitus, this complication was
a major risk factor for PDAC within this cohort (RR 13, 95% CI 3–65) [9, 29]. It is
reasonable to assume that diabetes is a risk factor for PDAC rather than just being a
symptom in HP patients. However, it remains possible that diabetes is a surrogate marker for
the severity of pancreatitis and thus the link to cancer is indirect.
In a separate study, pancreatic tissues from 43 patients with CP and 27 controls were
examined by immunohistochemistry and quantitative morphometry. The pancreatic volumes
were significantly reduced by about 20% in CP patients compared to controls, and beta-cell
areas were 0.69 % ± 0.08 % in CP patients and 0.97 % ± 0.08 % in controls, whereas alpha-
cell areas did not differ between the groups. The lack of increased beta-cell turnover in CP
patients, despite an approximately 10-fold increase in the number of apoptotic acinar cells,
suggests that the damage to the pancreas is highly specific for the exocrine compartment and
affects the endocrine islets to a lesser extent [30]. However, recent reports suggest that beta-
cell dysfunction develops in the early stages of CP while clinical diabetes manifests later,
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when there is profound fibrosis. This suggests that endocrine deficiency in CP is
multifactorial. Although the role of transcription factors (such as PDX-1, MafA, NeuroD) on
beta-cell function is understood, alterations in these factors in CP have not been elucidated.
Moreover, the role of PSCs on islet-cell function is still poorly understood. Hyperglycemia
and endothelin 1 have been reported to induce PSC activation, but the role of PSC activation
on islet-cell function remains unknown.
Role of PDX-1 in PDAC Development
Pancreatic duodenal homeobox 1 (PDX-1) is a master regulator of embryologic pancreatic
growth and development, and regulates insulin expression and islet maintenance in the adult
pancreas. However, it is also known that PDX-1 is an oncogenic transcription factor
regulating PDAC. Therefore, PDX-1 is a potential therapeutic target in PDAC. Treatment
with bifunctional human shRNA-PDX-1 significantly ablates human PDX-1-positive PDAC
in SCID mice and prolongs survival, and a synthetic human insulin promoter drives
expression of imaging genes in PDX-1-positive PDAC cell lines and tumors in mice [31].
Systemic delivery of the bifunctional shRNA(PDX-1) resulted in marked reduction of tumor
volume and improved survival in a human pancreatic cancer xenograft mouse model [32].
PDX-1 therefore appears to be a critical mediator of growth in normal and neoplastic
pancreatic tissue.
PANCREATOGENIC (TYPE 3c) DIABETES
Classification and prevalence of T3c diabetes mellitus (T3cDM)
T3cDM, also called pancreatogenic or apancreatic diabetes mellitus, and is a form of
secondary or Type 3 diabetes mellitus as defined by the American Diabetes Association
(ADA) and by the World Health Organization [33]. The exocrine pancreatic diseases
underlying T3cDM include acute and chronic pancreatitis of any etiology,
hemochromatosis, cystic fibrosis, fibrocalculous pancreatopathy, pancreatic trauma leading
to loss of pancreatic tissue, pancreatectomy, pancreatic agenesis, and pancreatic cancer. The
most common underlying disease is CP, accounting for about 75–80% of T3cDM patients
[34]. Pancreatic carcinoma accounts for 8 % of all T3cDM according to a recent study, but
T3cDM also frequently occurs after surgical treatment of benign or malignant disease.
Detailed data on T3cDM prevalence is scarce, due to lack of research on the issue and
difficulties with diabetes classifications [35].
Older studies estimated T3cDM to have a low prevalence of about 0.5–1.2 percent among
all cases of diabetes in North America, but recent data suggest that T3cDM might be more
common than generally believed. In Germany, Ewald et al investigated 1868 diabetic
patients seen at an academic medical center [34]. After comprehensive evaluation, 9.2% of
patients could be classified as T3cDM, using ADA criteria, of which 78% were also
diagnosed with CP. Most T3cDM patients were initially misclassified as T2DM. The
previous underestimation of the prevalence of T3cDM might be due to the fact that it has
become easier to detect exocrine pancreatic pathology as imaging methods of the pancreas
have improved, and noninvasive screening methods to quantify exocrine dysfunction, such
as fecal elastase 1, are now widely available [35].
In contrast to T1DM or T2DM, the endocrinopathy in T3cDM is complex and complicated
by additional comorbidities such as maldigestion of fats and proteins and malnutrition.
Exocrine insufficiency, a deficiency of fat-soluble vitamins (especially vitamin D) and
impairments of fat hydrolysis and incretin secretion are found very commonly in T3cDM
[36]. Pancreatic enzyme replacement therapy is therefore required in virtually all patients
with T3cDM [37].
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Treatment of T3cDM
Seventy-five percent of T3cDM is due to chronic pancreatitis, which carries a high risk for
pancreatic carcinoma. Insulin and insulin secretagogue treatment may increase the risk of
malignancy, whereas metformin therapy may reduce it. Metformin should therefore be the
first line of therapy, if tolerated, and continued if insulin treatment must be added for
adequate glucose control [37].
In advanced T3cDM, insulin replacement therapy is the only efficacious treatment option,
and patients should be treated using general insulin dosing and regimen guidelines for
T2DM [38]. In T3cDM, blood glucose control may be labile due to loss of glucagon
secretion, carbohydrate malabsorption, and/or inconsistent eating patterns due to pain and/or
nausea. Insulin pump therapy should be considered for patients who are able to manage this
form of treatment. In diabetes due to CP, therapy with insulin or insulin secretagogues
(sulfonylurea and glinides) may be necessary. Because secretagogues can cause
hypoglycemia, short-acting agents are preferred when meal ingestion is inconsistent.
Adverse effects associated with thiazolidinediones and potential risks of incretin-based
therapies (e.g. GLP-1 analogues and DPP-4 inhibitors) should preclude their use in T3cDM
outside of the context of formal clinical trials. Because T3cDM has the same incidence of
retinopathy as T2DM [39], surveillance for microvascular disease should be conducted as
for T1DM and T2DM.
Discrimination of T3cDM from T2DM
T3cDM differs from T2DM not only by the loss of insulin from beta-cells but also of
glucagon from alpha-cells and PP from PP- or F- cells, respectively. CP patients that have
pre-existing risk factors for T2DM, such as obesity, may have further difficulties with
glucose homeostasis, and a system for differentiating T3cDM from T2DM is needed. Ewald
and Bretzel suggested the following criteria for diagnosing T3cDM [35]:
Proposed major criteria (all must be fulfilled):
• Presence of exocrine pancreatic insufficiency (according to monoclonal fecal
elastase-1 test or direct function tests).
• Pathological pancreatic imaging (endoscopic ultrasound, MRI, CT).
• Absence of type 1 diabetes mellitus associated autoimmune markers
Minor criteria:
• Impaired beta cell function (e.g. HOMA-B, C-peptide/glucose ratio)
• No excessive insulin resistance (e.g. HOMA-IR)
• Impaired secretion of incretins (e.g. GLP-1)
• Low serum levels of lipid soluable vitamins (A, D, E, and K).
Despite these criteria, there is a degree of overlap between the different forms of diabetes
because long-standing T1DM and T2DM are associated with exocrine pancreatic failure,
and diabetics are at a higher risk for developing AP and/or CP. Furthermore, patients with
previous episodes of pancreatitis may develop T1DM or T2DM independently of their
exocrine pancreatic disease. The best discriminator of T3cDM from T2DM appears to be the
PP response to nutrients [38].
PP is localized predominantly to islets in the ventral portion (head) of the pancreas and is
promptly secreted in response to ingested nutrients. T3cDM secondary to cystic fibrosis, CP,
pancreatic malignancy, or pancreatic resection is uniformly characterized by a deficiency in
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the nutrient-stimulated release of PP. T2DM, on the other hand, is typically associated with
an increase in basal and nutrient-stimulated levels of PP, and healthy elderly subjects with
normal glucose tolerance also demonstrate elevations in basal and nutrient-stimulated levels
of PP compared with younger subjects. Therefore, the discrimination of T3cDM from
T2DM is based on the failure of plasma PP levels to increase after nutrient ingestion. Basal
levels of PP in PP-deficient subjects are similar to basal levels in normal subjects, so a
nutrient stimulus is required to confirm PP deficiency. Glucose ingestion is a relatively weak
stimulus for PP release, whereas a mixed nutrient meal is a strong inducer of PP release. A
standardized mixed-nutrient stimulus is 8 ounces of a liquid dietary supplement such as
Boost® or Ensure®; peak levels of PP are seen within 30–60 min after ingestion.
Role of pancreatic polypeptide (PP) in T3cDM
Enhanced sensitivity to insulin administration, due to prevailing insulin deficiency, was a
well-recognized consequence of pancreatogenic diabetes but it was not until euglycemic
clamp studies were performed with glucose tracer methodology that isolated hepatic insulin
resistance was discovered to coexist in the setting of increased peripheral insulin sensitivity
in animal and then clinical studies of T3cDM [37]. Isolated hepatic insulin resistance has
been documented in T3cDM due to CP, pancreatic resection, pancreatic cancer, and cystic
fibrosis, and results in persistent, unsuppressed hepatic glucose production. PP deficiency
has also been documented in CP [40], proximal or total pancreatectomy, and cystic fibrosis,
so it was identified as a likely mediator of the hepatic defect. Acute administration of PP
was found to have no effect on hepatic insulin sensitivity in normal or PP-deficient
individuals; however, prolonged PP administration was found to reverse the hepatic insulin
resistance in rats, dogs, and patients with T3cDM due to CP or pancreatic resection. Animal
studies confirmed that PP deficiency results in diminished hepatic insulin receptor (IR)
availability, and hepatic IR deficiency is reversed by prolonged PP administration [37]. In
clinical studies, PP administration reversed hepatic insulin resistance in patients with CP or
after proximal pancreatectomy, and resulted in improved glucose tolerance. Recently, a
randomized, placebo-controlled study in T1DM and T3cDM patients found that PP
administration enhanced insulin sensitivity and lowered the insulin requirements of these
patients [41].
Mechanism(s) of pancreatic cancer-induced T3cDM
While long-standing diabetes mellitus (DM) modestly increases the risk of PDAC, PDAC
also frequently causes DM. This “reverse causality” has greatly complicated epidemiologic
studies of the relationship between the two diseases [42]. More than half of PDAC patients
have DM or hyperglycemia, and the onset of DM typically occurs between 6 months and 36
months before PDAC diagnosis in 20–25 percent of patients. Furthermore, resection of the
PDAC leads to amelioration of DM in roughly half of new-onset DM subjects [43]. This
suggests that new-onset DM could be a biomarker of PDAC [44].
Hypotheses of how pancreatic cancer induces T3cDM
As in T2DM, beta cell dysfunction and peripheral insulin resistance are seen in PDAC-
induced DM (PDAC-DM). However, in contrast to T2DM, onset and progression of glucose
intolerance in PDAC-DM occur in the face of ongoing, often profound, weight loss. There
are several hypotheses for how PDAC might cause DM, including progressive pancreatic
tissue destruction due to the tumor growth, and metabolic consequences of cancer-related
malnutrition. The most likely explanation for the frequent occurrence of DM in PDAC,
however, is a paraneoplastic phenomenon caused by tumor-secreted products [45]. This
notion is supported by laboratory findings that supernatants from PDAC cell lines inhibit
insulin secretion.
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One such possible mediator of beta-cell dysfunction in pancreatic cancer-induced diabetes is
adrenomedullin, a pluripotent hormone with some homology to amylin, which is
overexpressed in PDAC [46]. Adrenomedullin receptors are found on beta- cells and its
expression is seen specifically in the F cells of the islets. Inhibition of insulin secretion was
replicated by external addition of adrenomedullin and abrogated by its genetic knockdown.
Similar effects were seen in orthotopic and subcutaneous in vivo tumor models using
adrenomedullin-expressing PDAC cell lines [45]. These findings support the notion that
adrenomedullin is a mediator of beta-cell dysfunction in PDAC. The cause(s) of insulin
resistance and PDAC-DM-associated weight loss remains unclear, though these appear to be
paraneoplastic phenomena as well [46].
GENOMIC ASSOCIATIONS OF CP, DM, AND PDAC
After several decades of research, a roster of genes has been identified for CP, DM, and
PDAC (Table 1), all three of which share three characteristics: familial aggregation and
familial clustering, which in are indicators of shared genetic and/or environmental
etiologies; variation in age at diagnosis, which has been linked in some subsets of patients to
familial risk; and a hereditary component as demonstrated by Mendelian segregation
analyses. For all three, epidemiologic risk factors (e.g. sex, obesity [DM], alcohol intake
[CP], and smoking [PDAC]) may interact with genetic factors.
Variants of approximately 30 genes have been found to confer genetic risk for DM, each
with a modest effect (e.g. PPARG and KDNJ11, identified through the candidate gene
approach; and TCF7L2, WFS1, HDF1B, FTO, CDKN2A, SLC20A8, among others,
identified through association and GWAS approaches) [47–50]. Research to date suggests
that susceptibility to DM is explained by a polygenic risk model, with each genetic variant
having a small effect, and none of which significantly improve risk assessment over
common risk factors such as age, sex, family history, BMI, and clinical measures [51].
Rather than a classic Mendelian disorder, recurrent AP and CP represent truly complex
diseases with the interaction and synergism of multiple genetic and environmental factors,
especially alcohol and smoking [52, 53]. However, much of the variability in susceptibility
to recurrent AP and CP is now clearly shown to be related to genetic factors, with PRSS1,
SPINK1, CTRC, CFTR, and CASR established as susceptibility loci for CP. Most recently,
a large two-stage GWAS analysis by Whitcomb et al [7] identified and replicated PRSS1-
PRSS2 and the X chromosome-linked CLDN2 as susceptibility loci, with the latter gene’s
variants potentially interacting with alcohol consumption.
Over the past decade, the efforts of the Pancreatic Cancer Genetic Epidemiology
Consortium (PACGENE), Pancreatic Cancer Case-Control Consortium (PanC4), and
PanScan have demonstrated that individuals with a family history of pancreatic cancer are at
an increased risk of developing pancreatic cancer. Overall, case-control studies have
estimated that the odds of having a family history of pancreatic cancer are 1.9- to 13-fold
higher in pancreatic cancer patients compared with healthy controls. A recent pooled
analysis of data from five cohort and one case-control study estimated the odds of pancreatic
cancer to be 1.76 higher among individuals with one first-degree relative and 4.26 higher
with two or more first-degree relatives with pancreatic cancer compared with those without
a family history of pancreatic cancer [54, 55].
A number of susceptibility genes have been identified [56]. The most commonly mutated
gene is BRCA2, with PALB2 the second most commonly mutated gene for hereditary
pancreatic cancer[57]. Carrying a disease-associated mutation in CFTR is associated with a
modest increase in risk for pancreatic cancer, with those affected generally diagnosed at a
younger age, especially among smokers; interestingly, clinical evidence of antecedent
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pancreatitis was uncommon among both carriers and noncarriers of CFTR mutations [58].
Next-generation sequencing studies indicate that inherited ATM mutations also play an
important role in familial pancreatic cancer predisposition [59].
GWAS studies of sporadic cases of pancreatic cancer have implicated regions that harbor
ABO, TERT, and CLPTM1L. The results are consistent with earlier epidemiologic evidence
suggesting that people with blood group O may have a lower risk of pancreatic cancer than
those with groups A or B [60]. Using GWAS data from 3,851 cases and 3,934 controls and a
logistic regression model for genotype trend effect that was adjusted for study, age, sex, self-
described ancestry, and five principal components, Petersen et al. identified eight SNPs that
map to three loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Two correlated SNPs,
rs9543325 and rs9564966, map to a nongenic region on chromosome 13q22.1. Five SNPs
on 1q32.1 map to NR5A2, and the strongest signal was at rs3790844. A single SNP,
rs401681 maps to the CLPTM1L-TERT locus on 5p15.33, which is associated with multiple
cancers [61]. Additional insights gained from pathway, candidate gene, and gene-
environment studies are now possible.
SURVEILLANCE OF INDIVIDUALS WITH HIGH RISK OF PANCREATIC
CANCER
Radiologic and cytogenetic detection of premalignant lesions
Management of patients at high risk for PDAC is important yet difficult because of
uncertainties regarding the method and frequency of screening methods, as well as concerns
about the potential harm from missing resectable and curable lesions compared to the risk of
removing lesions with low-malignant potential. There have been numerous small screening
studies performed in the US and Europe over the last decade [62–68] as well as ongoing
studies of PDAC genetic epidemiology [69–71]. Target lesions for pancreatic screening
include T1N0M0 margin-negative PDAC, high-grade dysplastic precursor lesions such as
PanIN-3, and intraductal papillary mucinous neoplasia with high grade dysplasia. Screening
and surveillance is also recommended for first-degree relatives (FDRs) of patients with
PDAC in at least two FDRs, patients with Peutz-Jeghers syndrome, and carriers of mutations
in familial PDAC susceptibility genes (p16, BRCA2, PALB2 and HNPCC-associated genes)
with at least one affected FDR. Pancreatic lesions are more common in older individuals, so
screening should generally be initiated at age 50 or 55 [69, 70, 72].
The initial screening test for cystic lesions should include endoscopic ultrasonography
(EUS) and/or MRI/magnetic resonance cholangiopancreatography (MRCP) based upon the
results of the CAPS3 trial that showed EUS and MRI/MRCP had similar accuracy at
detecting pancreatic cysts that exceeded the sensitivity of CT scanning [71]. When PDAC is
suspected, CT imaging using a pancreatic protocol is the best technique for evaluating solid
lesions. Because of the risk of post-procedure pancreatitis, endoscopic retrograde
cholangiopancreatography (ERCP) should only be used when there is a suspected neoplastic
main duct lesion identified by EUS or MRI/MRCP.
Because PanIN lesions can only be identified reliably by histological analysis of pancreatic
tissue, investigators have proposed several approaches to identify PanIN. One option
involves performing pancreatic tail resections for patients with diffuse pancreatic imaging
abnormalities and then proceeding to total pancreatectomy if PanIN-3 is detected [73, 74].
Other approaches are under investigation, including analysis of endoscopically-collected
pancreatic fluid for markers of PanIN-3 [75, 76], and molecular imaging approaches [77].
Subjects with subcentimeter branch duct-IPMNs identified by screening are currently
recommended to undergo surveillance annually or more often, depending on the size of the
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lesion. For high risk subjects with unifocal cysts or one dominant cyst with disturbing
features (mural nodule, duct dilatation, of several centimeters and increasing size), criteria
for resection at many screening centers have evolved to be similar to the criteria used to
manage sporadic lesions [78, 79]. There is no consensus on whether to perform partial or
total pancreatectomy for suspicious lesions identified by screening. Patients who undergo a
partial pancreatectomy are recommended to continue surveillance. Some centers will
perform a completion total pancreatectomy if PanIN-3 is detected in the resection specimen
rather than continue surveillance. Islet cell autotransplant after total pancreatectomy is not
recommended for patients with high risk of developing PDAC because of concerns of
reintroducing neoplastic cells into the patient’s liver.
Biomarkers for pancreatic screening and lesion characterization
An obstacle to detecting small early-stage pancreatic cancers is that very small cancers may
not produce a sufficient amount of material useful for a screening test. Improvements in
diagnostic imaging are needed, such as molecular imaging tools that improve the
discrimination of malignant cells from benign conditions such as plectin-based imaging
[77].
A variety of molecular targets are under investigation for their diagnostic utility in PDAC.
Although gene mutations are a major focus of biomarker efforts at early detection, other
biomarkers are under investigation including proteins [80], modified proteins such as
glycoproteins, miRNAs [81] and other non-coding RNAs. The tumor antigen, CA19-9 is a
glycoprotein, and further investigation of glycosylation abnormalities and glycoprotein
patterns may help identify diagnostic markers [82]. Furthermore, many individuals develop
antibodies to mutated proteins, overexpressed proteins, or altered forms of proteins that arise
during malignant progression of cancer, and these autoantibodies may be useful biomarkers
[83].
The main clinical scenarios in which biomarkers are needed include the detection of
asymptomatic T1N0M0 pancreatic cancers, the evaluation of pancreatic cysts, and the
detection of PanINs. While EUS-guided fine needle aspiration of solid masses has a high
cytological diagnostic yield, standard cytologic evaluation of pancreatic cyst fluid has
limited value, due to the paucity of cellular material in early non-invasive lesions and the
limited diagnostic utility of current marker tests. Sequencing IPMN cyst fluid DNA for
somatic mutations in candidate genes has led to the identification of oncogenic GNAS
mutations in 66% of IPMNs, and this approach is a focus of current investigation [84].
Cost-benefit analysis of screening and intervention in high-risk patients
The outcome measure of health services effectiveness is reported as quality-adjusted life
years (QALY), which combines the quantity and quality of life into one single index.
Quantity is defined as years of life, while quality is quantified through the concept of
“utility,” which incorporates a patient’s preference for a specific state of health. Cost-
effectiveness analysis is generally more useful when the diagnostic indications and tests and
subsequent management is relatively agreed upon and standardized. Cost effectiveness
analysis studies have been performed in the setting of screening asymptomatic members of
familial pancreatic cancer kindreds, and illustrate that current knowledge gaps prevent cost-
effectiveness determinations in pancreatic cancer screening [85].
Because no consensus guideline for clinical use exists, screening is typically done in
association with research studies linked to a registry and with protocol-directed collection of
blood, urine and/or pancreatic juice. Most academic centers recommend EUS every year
starting at age 50 or 10 years younger than the earliest age of onset in patients who are first
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degree relatives in familial pancreatic cancer syndromes, and first or second degree relatives
in gene carriers for diseases associated with an increased risk of PDAC and hereditary
pancreatitis. Other centers use MRI instead of EUS. The rationale is that MRI appears to
have similar sensitivity for cystic lesions but because of volume averaging, small cancers
may be missed, and cancers outside of dominant cysts may also be missed. The frequency
and type of follow-up testing depends on the presence of high risk biomarkers and co-
morbid conditions that may affect the decision for definitive treatment, such as total
pancreatectomy
THE EFFECTS OF DIABETES TREATMENT ON PDAC
In addition to diet and exercise, commonly used drugs to treat T2DM include sulfonylureas,
metformin, thiozolidinediones, alpha-glucosidase inhibitors, glucagon-like peptide-1
(GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors. In addition, there
are various forms of insulin, including insulin glargine, a long-acting recombinant insulin
that exhibits an increased binding affinity toward the insulin- and insulin-like growth
factor-1 receptors. While several studies have suggested that insulin glargine may increase
slightly the risk of certain cancers, including possibly PDAC, other studies have failed to
show such an association. Sulfonylureas, thiozolidinediones, and alpha-glucosidase
inhibitors appear to have little or no effect on the risk of PDAC.
Metformin is a biguanide that acts principally to decrease hepatic glucose output. Several
retrospective studies of diabetic patients and three case-control studies of patients with
pancreatic cancer have reported that metformin use is associated with a reduced risk of
PDAC [86]. It has also been reported that metformin use was associated with a longer
overall survival time and lower mortality in patients with PDAC and DM, and that
metformin may help reduce the risk for PDAC [87]. However, two cohort studies of diabetic
patients did not confirm that metformin lowered the risk for pancreatic cancer. In view of
the limitations of retrospective studies due to multiple potential biases, there is clearly a
need for large scale studies to assess the effects of metformin as well as other glucose-
lowering agents on the pancreas [88].
Mechanisms of action of incretins
GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are intestinal derived
incretins which potentiate glucose-stimulated insulin secretion by the beta cell, inhibit
glucagon release by the alpha cell, and promote beta cell growth and survival. GLP-1
acutely stimulates glucose-dependent insulin release through increased production of intra-
cellular cAMP, and exerts chronic effects that prevent beta cell exhaustion by ensuring that
insulin mRNA stability is increased and insulin stores are refilled. GLP-1 also upregulates
PDX-1 expression and induces its translocation to the nucleus, leading to enhanced insulin
gene transcription [89]. GLP-1 also acts to suppress beta-cell apoptosis. Thus, GLP-1
promotes beta cell proliferation, and beta-cell survival [90].
GLP-1 mimetics such as exendin-4 (exenatide) and liraglutide interact directly with the
GLP-1 receptor, whereas DPP-4 inhibitors such as sitagliptin, saxagliptin, and linagliptin
increase endogenous levels of GLP-1 by interfering with its DPP-4-mediated degradation.
GLP-1 receptors are expressed on various cell types, including beta cells, pancreatic duct
cells, pancreatic duct glands, acinar cells, and cells within PanIN lesions. Therefore, in
addition to its effects on the beta cells, GLP-1 can exert trophic effects on these other cell
types. For example, GLP-1 may promote mitogenic signaling in human pancreatic ductal
cells by activating the GLP-1 receptors on these cells. These observations underscore the
importance of assessing the potential role of GLP-1 receptor agonists in the human pancreas.
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Results from a human pancreatic biobank study
To explore this issue, a recent study examined autopsy-obtained pancreata derived from 7
T2DM patients who had been treated with sitagliptin and one who had been treated with
exenatide (a GLP-1 homologue) [91]. These pancreata were ~40 percent larger than
pancreata from 12 donors with T2DM who had not been treated with incretin mimetics
(control group). Cell proliferation and the frequency of PanIN lesions were increased in the
incretin group compared with the control group. In addition, the incretin group exhibited
alpha cell hyperplasia and glucagon-expressing microadenomas (3/8) and one pancreas
harbored a glucagon-expressing neuroendocrine tumor (NET). By contrast, no glucagon-
expressing microadenomas or NETs were present in the pancreata from the control group.
These alterations, combined with an increased number of PanIN lesions adjacent to ducts,
could potentially contribute to obstruction-associated alterations and pancreatitis during
long-term incretin mimetic therapy. However, the incretin mimetic group was on average 18
years older than the control group, which may have affected the results as the incidence of
PanIN lesions increases with age. The increased size of the pancreata in the incretin-treated
cohort remains unexplained, but the effect was primarily due to inclusion of two morbidly
obese men (BMI > 40) and a severely obese woman (BMI > 35) in the incretin mimetic
group. Also, the pancreas sizes were not controlled for sex (male pancreata tend to be larger)
or visceral fat in the pancreas of obese subjects [92]. Additional clinical studies are therefore
required to assess the consequences of incretin mimetic therapy on the pancreas, especially
because a study with diabetic rats suggested that GLP-1 may cause pancreatic abnormalities
including pancreatic ductal hyperplasia [93] and a study using a genetically engineered
mouse model of pancreatic cancer in which oncogenic Kras is expressed revealed that 12
weeks of treatment with Exendin-4 led to accelerated PanIN and desmoplastic progression
[94].
Industry perspective on pancreatitis and pancreatic cancer risk with liraglutide
Treatment of T2DM patients with liraglutide, a long-acting GLP-1 receptor agonist, have
not shown any evidence of a risk of pancreatitis or PDAC. Studies in mice, rats, and
cynomolgous monkeys did not reveal any hyperplasia, PanINs, metaplasia, or endocrine
tumors. Similarly, studies in diabetic Zucker rats did not reveal any drug induced effects. In
humans, in over 6,500 patients and greater than 5,000 patient-year exposures, there were two
patients with pancreatic cancer after 152 and 7 days of therapy, respectively, and a third
patient was diagnosed with pancreatic cancer prior to randomization. With respect to AP,
there was a 1.8-fold increase in incidence per 1,000 patient-year exposure which
approximated the range anticipated in a population of individuals with T2DM (0.55 to 1.37
cases per 1,000 patient-years). Interestingly, unrelated to therapy, lipase levels were
increased in 20% of T2DM and fluctuated over time. Studies in mice, rats, and monkeys
given high doses of liraglutide did not reveal any histological evidence for pancreatic
inflammation or PanIN formation.
In humans, a causal relationship between liraglutide and AP or PDAC can neither be
established nor excluded based on current data. However, prospective, controlled and
independently adjudicated data are being collected from several ongoing clinical trials,
including a large 9,000-patient cardiovascular outcome trial (LEADER®). Data from post-
marketing safety surveillance and independently submitted reports to regulatory agencies
over the last 3–4 years have not identified an association between liraglutide and pancreatic
pathology. Two prospective epidemiological studies, based on a claims-database in the
United States and a medical record database in the United Kingdom, are currently being
conducted and will provide valuable additional information.
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Industry perspective on pancreatitis and pancreatic cancer risk with sitagliptin
In studies with mice, rats, monkeys, and dogs, the DPP-IV inhibitor sitagliptin was not
associated with any episodes of pancreatitis, gross alterations in the pancreas, or
histomorphological changes in the pancreas. In humans, a post hoc analysis of reported
adverse events of pancreatitis and pancreatic cancer was carried out using a pooled
population of nearly 15,000 patients. Slightly more than half of these patients were
randomized to receive sitagliptin (100 mg/day), for at least 12 weeks, with some patients
receiving the drug for up to 2 years. To take into account potential differences between
groups in relation to duration of exposure to treatment, reports of adverse events were
expressed as exposure-adjusted incidence rates (numbers of patients with events per 100
patient-years). The mean duration of exposure was 284 days for the sitagliptin group and
264 days for the comparison group. For the composite endpoint of pancreatitis (which
included the terms “pancreatitis” and “pancreatitis acute”), exposure-adjusted incidence
rates were similar for both groups (0.08 and 0.09 events per 100 patient-years in the
sitagliptin and comparator groups, respectively). A similar pattern was observed with an
expanded composite which added the term “pancreatitis chronic”, with 0.13 and 0.09 events
per 100 patient-years in the sitagliptin and comparison groups, respectively [95].
For the composite endpoint of pancreatic cancer (including the terms “adenocarcinoma of
pancreas,” “pancreatic carcinoma,” and “pancreatic carcinoma metastatic”), the exposure-
adjusted incidence rates were similar in the two treatment groups (0.05 and 0.06 events per
100 patient-years in the sitagliptin and comparison groups, respectively). These data from
sitagliptin clinical trials are consistent with a published meta-analysis of clinical trials
involving multiple DPP-4 inhibitors [96]. In view of the long latency period for the
development of pancreatic cancer, data from longer term studies are required. Such data will
be available from a sitagliptin cardiovascular outcomes study of over 14,000 patients
(TECOS), and cardiovascular outcome studies with other DPP-4 inhibitors.
Pitfalls in studies of adverse drug effects
Given the large number of patients with T2DM who take anti-diabetes medications on a
long-term basis, any protective or harmful effects of these medications on cancer risk, even
at a relatively modest magnitude, could have significant public health implications. Ideally,
one should conduct randomized controlled trials (RCTs) to assess drug risk. Because the
sample size and follow-up duration are seldom sufficient for cancer outcomes in such
studies, post-marketing surveillance is critical. This includes spontaneous adverse event
reporting systems and formal phase IV studies. However, spontaneous reporting is subject to
reporting bias and rarely guides practice. Post-marketing RCT may inform safety, but are
only occasionally available. While observational studies involving large populations and
extensive person-years of drug use are important phase IV studies, they are prone to various
biases. These include confounding by indication, as in the case of the choice of anti-diabetes
therapy being dictated by factors such as severity of diabetes. Smoking, diet, physical
activity, compliance/adherence, and comorbidity status also need to be considered, since
they may influence cancer risk. Another concern is protopathic bias, which occurs when
treatment for the early symptoms or other consequences of a disease appears to cause the
disease. This is usually associated with an inverse duration-response effect between the
exposure and outcome, and is of concern when evaluating the association between diabetes
medications and pancreatic cancer. For example, a reported association between short-term
exposure to anti-diabetes medications and the risk of pancreatic cancer disappeared or was
significantly decreased after longer duration of exposure. Incorporation of a lag-time in
exposure definition helps to control for protopathic bias.
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Time-related biases are common and give the incorrect appearance that a medication
reduces the risk of developing the outcome of interest. They include immortal time bias in
which treatment status involves a delay during which follow-up time is accrued, time-
window bias in case-control studies due to differences in exposure opportunity time
windows between cases and controls, and time-lag bias which occurs when different classes
of diabetes treatments are prescribed at different stages of diabetes. It is therefore important
to use appropriate statistical methods that minimize these biases.
FDA surveillance of adverse drug effects
Investigational drugs are subject to extensive non-clinical testing, including 6- to 9-month
studies in rodents and non-rodents, and 2-year evaluation of carcinogenicity in rats and
mice. Although pancreatic toxicity or pancreatic neoplasms have not been observed with
incretin mimetics, carcinogenicity studies revealed that acinar and islet hyperplasia or
hypertrophy, inflammation, and acinar atrophy, were occasionally present in treated animals.
These changes were of minimal severity, and modest increases in either incidence or
severity were observed only at the highest dose evaluated, which is several-fold higher than
used in humans.
Because GLP-1-based therapeutics may exert adverse effects on the exocrine pancreas under
pathophysiological conditions that predispose to pancreatitis, such as T2DM, the FDA
issued a post-marketing requirement (PMR) on the sponsors of exenatide, liraglutide, and
sitagliptin to conduct a pancreatic toxicology study in a rodent model of T2DM. Three such
studies that met PMR criteria were submitted to the FDA for review, and none demonstrated
a treatment-related adverse effect on exocrine histology or proliferation. FDA veterinary
pathologists reexamined the histological slides from one of these studies and concluded that
treatment could cause mild changes, such as peri-ductal inflammation, islet degeneration,
and intraluminal concretions.
The FDA also initiated research into identifying an experimental model that would enable a
comparative toxicological assessment of potential pancreatic toxicity for investigational
GLP-1-based therapies currently under development. Chemically induced models of
pancreatic injury, Zucker Diabetic Fatty rats, and mice fed a standard or high-fat diet have
thus far been investigated. Mice fed a high-fat diet and administered exenatide displayed a
time- and dose-dependent exacerbation of acinar cell hyperplasia, atrophy, fibrosis, and
increased peri-ductal inflammation. The effect of exenatide was multi-focal and associated
with histological changes of minimal to moderate severity, but not with any effects on
animal morbidity or mortality. The FDA has continuously monitored the GLP-1-based
therapies since initial approval of these two drug classes, and continued non-clinical
investigation remains an important component of the FDA’s efforts to clarify the potential
pancreatic toxicity of the GLP-1-based therapies.
FDAs approach to addressing a pancreatic safety signal with incretin mimetics
The market share for incretin mimetics in T2DM therapy is roughly 10%, and there is
insufficient information to characterize safety profiles for these drugs. Therefore, post-
market safety and surveillance are crucial, and the FDA Adverse Event Reporting System
(FAERS) is functioning well in this regard. While pharmacovigilance and
pharmacoepidemiology are used by the FDA to address pancreatic safety signals, there is
also concern regarding published studies that suffer from limited power and incomplete
validation. Cases of acute pancreatitis (AP), including necrotizing and hemorrhagic
pancreatitis in association with incretin therapy in T2DM, have been reported to AERS in
the post-marketing setting, and a recent analysis of admissions for acute pancreatitis among
diabetic subjects revealed an increased association with incretin-based therapies [97]. Safety
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concerns regarding these drugs have therefore been the subject of multiple FDA reviews and
labeling changes. Published data mining analyses of the publicly available AERS data raised
concerns regarding the risk of acute pancreatitis, pancreatic cancer, and thyroid cancer in
association with incretin mimetic therapy [98]. Limitations of AERS data include under-
reporting, lack of an accurate population denominator, adequate control data, and inadequate
clinical documentation. It is therefore not possible to calculate incidence rates and establish
causality based on such data. The FDA has therefore issued safety communications and
added information in the Important Limitations of Use subsection of the Indications and
Usage Section, the Adverse Reactions, Post-marketing subsection, and the Patient
Counseling Information Section to warn patients of the risk of acute pancreatitis. The FDA
has also required the manufacturers to conduct epidemiological studies of pancreatic toxicity
in order to confirm and quantify the potential association with GLP-1 therapies in T2DM,
and that cases of pancreatitis and pancreatic cancer be reported as adverse events of special
interest in large cardiovascular outcome trials that are required for the GLP-1 based
therapies. The signal for medullary thyroid cancer, a rare form of thyroid cancer that has
been observed in animal studies with long-acting GLP-1 agonists, is labeled in a Boxed
Warning in all approved long-acting GLP-1 agonists (liraglutide and exenatide). Moreover,
the FDA has required that all manufacturers of approved GLP-1 agonists participate in a
Medullary Thyroid Cancer Registry as a post-marketing requirement. Importantly, to date, a
causal link between GLP-1-based therapies and the risk of AP has not been established, and
evaluation of the potential association between GLP-1-based therapies and pancreatitis and
pancreatic and thyroid cancers will require adequately powered, long-term epidemiological
studies.
GAPS AND OPPORTUNTIES FOR FURTHER RESEARCH
Gaps in our knowledge exist across the full spectrum of pancreatic cancer. The failure to
diagnose PDAC at an early stage as well as an aggressive pattern of metastasis both
contribute to the dismal outcomes with this disease. For this reason, continued emphasis
should be placed on both early diagnosis and therapy. The major challenge for the future,
given the incidence of this disease, is the development of strategies for early detection that
focus on cost-effective and transportable tests to identify high-risk subjects..
Clinical Trials
Advancing the clinical care of patients with PDAC will require improving biorepositories
and developing a roadmap to prioritize therapeutic targets in clinically relevant models.
Therapeutic intervention in the adjuvant setting may be preferable to eliminate some of the
challenges of drug development in the advanced disease setting [99]. The emphasis must
therefore be on performing well-designed phase II studies with uniform sets of basic entry
and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or
locally advanced PDAC must be studied separately [100].
Pancreatic Stellate Cell Studies
Despite the increasing recognition of the tumor microenvironment and tumor-stromal
interactions as significant contributors to PDAC, there remain significant gaps in knowledge
regarding the role of PSCs. The origin of PSCs is not clear, but some investigators have
identified the bone marrow as a source of a proportion of PSCs found in the pancreas.
Although many investigators have identified PSC-derived factors that promote PDAC, it is
unclear which mechanisms are most critical to PDAC progression. Evidence suggests that
PSCs play a role in metastasis, but the precise mechanisms are still lacking. The PDAC-
associated stroma represents an attractive target for novel therapies, but recent attempts to
inhibit the stroma to improve response to chemotherapy have failed in clinical trials.
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Whether the stroma of PDAC is a rational target for novel therapies, and if so, what the best
strategy is to inhibit the stroma, are issues yet to be resolved.
CCK receptor studies
Because CCK receptors are expressed by PSCs and responsible in part for collagen
production [101], will treatment with CCK receptor antagonists stop or prevent fibrosis in
patients with CP? Since CCK receptors are over-expressed in PDAC, could CCK receptor
antagonists be a reasonable preventative therapy in high risk individuals? Are CCK
signaling pathways reasonable potential targets for PDAC treatment? Do high fat diets
stimulate endogenous CCK release, and subsequently stimulate growth of tumors via CCK
receptors? What is the role of CCK in pancreatic regeneration, in cross-talk between cells in
the developing pancreas, and in malignant transformation?
The role of CP in PDAC development
If future epidemiologic studies of CP are to proceed, the clinical definition of CP needs to be
carefully defined (i.e., self-report vs. clinician diagnosis) and the actual prevalence of CP
needs to be established. In general, pancreatitis is considered as three basic categories -- AP,
recurrent AP, and CP – as part of a disease continuum. Further information is needed on the
factors which determine progressing through such a continuum. Some microbes directly
infect the pancreas, but it unclear what the role of microbial components play in CP and
PDAC. The cellular origin of PDAC remains unclear, and the factors which mediate acinar
to ductal metaplasia (ADM) and the early initiation of PanIN formation need further
examination. ADM has been observed in CP as well; will a better understanding of ADM
increase our success in screening and prevention of PDAC? Epidemiologic studies are
needed to determine if CP patients who present with (Type 3c) diabetes should be screened
and monitored for PDAC development. Can the specificity of screening be improved with
multiple serial markers and tests (biomarkers, mutations, hyper-methylation in pancreatic
juice, markers of activation of pancreatic stellate cells) and imaging (EUS, other imaging,
targeted imaging, computer-aided diagnosis)? It seems reasonable to imagine that multiple
biomarkers and imaging technologies may improve the predictive ability to identify high-
risk CP patients, but which tests, and how many tests will be necessary? Will such screening
approaches in high risk persons be cost-effective?
Pancreatic screening and markers of pancreatic neoplasia
There are numerous gaps in our understanding of the benefits and potential risks of
pancreatic screening. Further research is needed to improve the risk stratification of subjects
undergoing pancreatic screening, and to better identify non-genetic risk factors associated
with PDAC. Continued screening of high risk individuals will generate better estimates of
the prevalence of different grades of IPMNs and PanINs and invasive cancers for different
genetic and familial backgrounds and other risk factors. This information is needed to
determine what is the most appropriate age to initiate screening, and how often subjects
should be screened. We also need to better understand the natural history of PanIN and
IPMN lesions, and to develop biomarkers and molecular imaging methods to reliably detect
high-grade pancreatic neoplasia and early-stage invasive cancer.
T3cDM Diagnosis and Treatment Implications
Further studies are needed to evaluate the pathophysiology of T3cDM caused by CP, PDAC,
pancreatic resection and cystic fibrosis. Specific issues that require clarity include the best
criteria for differentiating T3cDM from T2DM, an assessment of the incidence of T3cDM in
PDAC and diabetic populations in general, and an assessment of the effect of various
diabetic drug treatments on the subsequent risk of PDAC in T3cDM patients. Additional
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studies are needed to establish a standard provocative agent for assessment of nutrient-
stimulated hormone (e.g., GLP-1 and PP) release in diabetic subjects, so as to discriminate
T3cDM from T2DM. Studies are also needed to determine how PP levels compare to other
measures of beta-cell function and insulin sensitivity in the development of T3cDM, as well
as the possible role of PP in the treatment of T3cDM. An evaluation of the long-term
glycemic control and rate of diabetes-associated complications of T3cDM patients with
early insulin treatment compared with oral therapy is also needed.
Diabetic Pharmacotherapy Associations with PDAC
Large consortium studies are needed to compare new-onset and long-duration diabetic
populations to determine the effects of antidiabetic treatments on the risk of PDAC. A
randomized trial of incretin and other antidiabetic agents in T2DM subjects is needed, with
periodic imaging of pancreatic size, measurement of pancreatic enzyme and GLP-1 levels,
and islet cell products such as chromogranin-A and glucagon. A multi-site survey of autopsy
findings in diabetic subjects, similar in design to the recent study by Butler et al [91], should
be conducted.
SUMMARY AND CONCLUSIONS
Several themes emerged from the workshop. First, the relationship between pancreatitis,
diabetes and PDAC is complex, but complexity is confounded by reverse causality. CP can
cause diabetes by destruction of the islets (Type 3c) resulting in the loss of glucagon and PP
in addition to insulin, with a high risk of hypoglycemia. The risks of T3cDM and CP are
additive in hereditary pancreatitis, but the specific PDAC risk of T3cDM in epidemiology
studies is not known because it has not been specifically measured.
Recent reports in the medical literature and lay press have raised major concerns about the
risk of PDAC in patients taking GLP-1 agonists or DPP-4 antagonists. The reports are
primarily case-control studies using existing databases and a small report of autopsy
findings [91]. The majority of the variation in case-control studies appeared to be related to
the control groups. Patients with diabetes are at increased risk of PDAC regardless of
treatment, and new onset diabetes in an older population may be a biomarker of occult
cancer, thereby confounding outcome measures. Prospective, randomized control trials have
not revealed any association between GLP-1 or DPP4 agents and PDAC, although the
duration of treatment was limited. In addition, animal studies including over 18,000 animals
using doses of GLP-1 agonists or DPP-4 antagonists that were many times higher than doses
given to humans did not reveal any signal of either pancreatitis or PDAC, or premalignant
lesions at rates higher than controls – and these findings were independently confirmed by
studies done by the FDA. Finally, the relationship between anti-diabetic agents, PDAC and
the public welfare are the responsibility of the FDA, and the presentations on the process of
evaluating medical reports, public concerns, animal data and human trials are handled with
vigilance and objectivity. To date, the FDA has not seen a convincing signal between the use
of GLP-1 or DPP-4 agents and PDAC, but they continue to monitor new findings and
carefully evaluate them.
The value of open exchange of ideas and information from multiple branches of medicine
and academics, industry and government was obvious to all in attendance. It is anticipated
that the foundations established by this Workshop will provide groundwork for many
productive programs and projects that will optimize patient treatment and reduce suffering,
especially the burden of disease caused by PDAC.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Established risk factors for pancreatic ductal adenocarcinoma.
Table 1. Risk Factor OR, Confidence Interval* Reference
Lifestyle Smoking
1.75
CI 1.61–1.87 Iodice, 2008 [102]
Alcohol (>4 drinks/day) 1.5 Lucenteforte, 2012 [103]
Occupational Chlorinated hydrocarbons 1.4–4.4 Andreotti, 2012 [104]
Polycyclic aromatic hydrocarbons (PAH) 1.5 Andreotti, 2012 [104]
Diet n-nitroso containing foods
1.27
CI 1.09–1.48 Risch, 2012 [105]
saturated fat/animal fat 1.5 Sanchez, 2012 [106]
Medical Pancreatitis
5.1
CI 3.5–7.3 Raimondi, 2010 [8]
- Chronic pancreatitis
13.3
CI 6.1–28.9 Raimondi, 2010 [8]
- Hereditary pancreatitis
69.9
CI 56.4–84.4 Raimondi, 2010 [8]
Allergies
0.73
CI: 0.64- 0.84 Olson, 2012 [107]
Diabetes mellitus 1.5 Li, 2012 [87]
Obesity 1.3 Bracci, 2012 [108]
Non-type O blood groups
1.65
CI 1.30–2.09 Risch, 2012 [105]
Genetics BRCA2
3.5
CI 1.87–6.58 Klein, 2012 [55]
STK11/LKB1
132
CI 44–261 Klein, 2012 [55]
PALB2 Familial** Jones, 2012 [57]
CDKN2A 12–38 Klein, 2012 [55]
CFTR 5.3–6.6 Raimondi, 2009 [109]
TP53 Familial** Raimondi, 2009 [109]
APC
4.46
CI 1.2–11.4 Raimondi, 2009 [109]
Mismatch repair genes 0–8.6 Klein, 2012 [55]
PALLD Familial** Pogue-Geile, 2006 [110]
1q32.1 locus
0.77
CI 0.71–0.84 Petersen, 2010 [61]
13q22.1 locus
1.26
CI 1.18–1.35 Petersen, 2010 [61]
GGT1
1.86
CI 1.11–3.15 Diergaarde, 2010 [111]
Factors are classified by environmental, medical and genetic categories. Bold risk factors indicate very high risk or odds ratio (OR) for pancreatitis
and familial cancer syndromes. Abbreviations in italics are standard gene symbols.
*Confidence intervals are given for meta-analyses.
**
Risk for familial cancer is high, but not comparable to population-based studies.
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References are from recent reviews or recent primary sources.
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